Please ensure Javascript is enabled for purposes of website accessibility

Why 180 Life Sciences Stock Is Falling Today

By Cory Renauer – Aug 19, 2021 at 1:08PM

Key Points

  • 180 Life Sciences went public through a merger with a special purpose acquisition company that had raised over $100 million last November.
  • The company intends to raise around $15 million in a private placement that will significantly dilute the stock's value for existing shareholders.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Another capital raise less than a year after the company's stock market debut is more than a little troubling.

What happened

Shares of 180 Life Sciences (ATNF 1.60%), a clinical-stage drugmaker, are under pressure. Investors aren't happy because the company has announced the second dilutive capital raise since it completed a transaction with KBLM Merger Corp IV to gain its stock market listing last year. The stock was down 26.7% as of 12:23 p.m. EDT Thursday.

So what 

The special purpose acquisition company, or SPAC, that took 180 Life Sciences public raised $115 million to identify and acquire a healthcare company with potential. This probably should have been more than enough to fuel 180 Life Sciences' relatively unambitious development pipeline, but it was not. 

Physician at work.

Image source: Getty Images.

180 Life Sciences finished June with less than $2 million in cash on its balance sheet. In order to raise an estimated $15 million, the company will issue 2.5 million new shares and warrants to purchase another 2.5 million shares.

The company's latest capital raise is suspiciously close to an $11.7 million private placement in February that was even more dilutive than the latest. That's a lot of share dilution for a company that only had around 18 million shares outstanding shortly after going public last November.

Now what

At the moment, 180 Life Sciences doesn't have any drugs of its own in clinical trials. Instead, it has some new method-of-use patents regarding AbbVie's top-selling anti-inflammatory treatment, called Humira.

AbbVie's mega-blockbuster is an anti-tumor necrosis factor (anti-TNF) injection used to treat rheumatoid arthritis, psoriasis, and a handful of less common inflammatory disorders. The antibody itself lost patent protection years ago and 180 Life Sciences has been able to patent methods of using it to treat rare inflammatory disorders that AbbVie probably never bothered with. This is an interesting business plan worth keeping an eye on, but I hardly expect it to work out in the long run.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

180 Life Sciences Corp. Stock Quote
180 Life Sciences Corp.
$0.45 (1.60%) $0.01
AbbVie Stock Quote
$159.62 (0.14%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.